FDA: Bausch Health’s Duobrii promotions misleading

The FDA has charged Bausch Health with making false or misleading claims about its topical plaque psoriasis cream Duobrii.
A fixed combination of tazarotene and halobetasol propionate lotion, Duobrii was approved by the FDA to treat plaque psoriasis in 2019.
In a March 31, 2022, letter to the company, the FDA’s Office of Prescription Drug Promotion (OPDP) called out a video, which aired on network television, for failing to include information regarding potential embryofetal risk or the risk of photosensitivity or sunburn.
“By omitting serious risks associated with Duobrii and

The FDA has charged Bausch Health with making false or misleading claims about its topical plaque psoriasis cream Duobrii.
A fixed combination of tazarotene and halobetasol propionate lotion, Duobrii was approved by the FDA to treat plaque psoriasis in 2019.
In a March 31, 2022, letter to the company, the FDA’s Office of Prescription Drug Promotion (OPDP) called out a video, which aired on network television, for failing to include information regarding potential embryofetal risk or the risk of photosensitivity or sunburn.
“By omitting serious risks associated with Duobrii and